The Federal Trade Commission, Department of Justice’s Antitrust Division, and U.S. Department of Health and Human Services jointly issued a Request for Information requesting public comment on transactions in the healthcare space. According to the agencies, there is increasing concern that private equity firms and other corporate owners are increasingly involved in healthcare transactions leading to greater consolidation, poorer quality of care, and less access to affordable healthcare. Continue reading “FTC, DOJ and HHS Launch Cross-Government Investigation Into Healthcare Competition”
NCAA Prohibited from Blocking NIL Compensation by Member Schools
A federal district court granted a preliminary injunction preventing the NCAA from enforcing one of its bedrock rules—that member institutions cannot directly compensate student athletes for name, image, and likeness (NIL). For over 100 years, NCAA bylaws prohibited payments to students representing member institutions in intercollegiate games to maintain amateurism across college sports. In recent years, due largely to mounting antitrust losses, the NCAA has allowed college athletes to earn compensation for their NIL but has prohibited compensation by schools and their boosters (so-called NIL collectives) related to the recruiting and transfer process. Believing that those prohibitions likely violate federal antitrust laws and harm students, the Tennessee federal court has preliminarily enjoined the NCAA from enforcing that restriction in State of Tennessee, et al. v. NCAA, No. 3:24-cv-00033.
Continue reading “NCAA Prohibited from Blocking NIL Compensation by Member Schools”
Federal and State Antitrust Enforcers Reiterate Focus on Healthcare
Federal and state antitrust enforcers are keenly focused on potential anticompetitive conduct in the healthcare space.
Federal Trade Commission Chair Lina Kahn recently noted that “the FTC is squarely focused on tackling illegal business practices that deprive Americans of access to affordable and innovative healthcare” in a speech to the American Medical Association’s national advocacy conference. According to Chair Kahn, medical professional consistently express frustration to the FTC “about how the business of healthcare today forces many [medical providers] to subordinate [their] own medical judgment to corporate decision-makers at the expense of patient health.” In response to those complaints, Chair Khan highlighted a few recent enforcement efforts, including scrutiny of group purchasing organizations, drug wholesalers, and pharmacy benefit managers; tackling unlawful consolidation in healthcare markets and roll-ups of healthcare providers. She also touted the FTC’s work protecting healthcare workers, tackling unlawful practices by pharmaceutical companies, including suits to block two major pharmaceutical mergers, and protecting patient privacy and data.
Continue reading “Federal and State Antitrust Enforcers Reiterate Focus on Healthcare”
Guidance for Controlling Drug Prices
The Federal Trade Commission (FTC) has announced its support of the federal government’s use of “march-in rights” as a mechanism to control the price of pharmaceuticals. The National Institute of Standards and Technology (NIST) late last year issued its “Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights” that would fundamentally change the use of march-in rights by allowing the government to exercise price control under the Bayh-Dole Act, which the FTC announced its support for last week. This shift is the latest effort by federal agencies to lower drug prices in the wake of President Joe Biden’s Executive Order on Promoting Competition in the American Economy.
Is Misclassification of Workers an Unfair Method of Competition?
The Federal Trade Commission (FTC) is signaling its intent to get further involved in employment practices after its activity of the last year and a half in proposing a ban on noncompete clauses in employment contracts and signing a memorandum of understanding with the U.S. Department of Labor (DOL) to bolster the FTC’s efforts to promote competitive U.S. labor markets.
New Bill Keeps Predictive Tech Under Scrutiny with Price Fixing
Several Democratic senators introduced a bill intended to stop companies from utilizing predictive technology to raise prices. Businesses are increasingly delegating important competitive decisions, including price-setting power, to artificial intelligence, algorithms, and other predictive technology software. Read more on the Duane Morris Artificial Intelligence Blog.
Preserve Materials During Pendency of Antitrust Investigation, FTC Says
Companies and individuals must be aware of their legal obligations to preserve communications when involved in government investigations or litigation, especially in light of new preservation standards from the Federal Trade Commission and Department of Justice. Due to concerns with the increased use of collaboration tools like Microsoft Teams and ephemeral messaging applications like Signal, the agencies are updating the language they include in standard preservation letters and requests for information, including second requests, voluntary access letters, civil investigative demands, other compulsory legal processes and grand jury subpoenas.
Senator Echoes FTC’s Focus on Improper Listings and Anticompetition
In January, Senator Tammy Baldwin (D-WI) sent letters to companies warning of improper Orange Book listings of patents for inhalers, following up on the FTC’s focus on potential anticompetitive harm of improper listings. According to Senator Baldwin’s letters, the recipients of the letters were warned by the FTC in November regarding the listing of inhaler patents, but have not removed the patents from the Orange Book. The letters follow an investigation launched earlier this month by the Senate Committee on Health, Education, Labor, and Pensions (of which Senator Baldwin is a member) into the prices of inhalers.
Senator Calls on Inhaler Companies to Stop Unfair Practices
Senator Tammy Baldwin (D-WI) sent letters on January 29 to companies warning of improper Orange Book listings of patents for inhalers, following up on the FTC’s focus on potential anticompetitive harm of improper listings.
GenAI and FTC Inquiries
The Federal Trade Commission announced on January 25 that it has begun an investigation into Generative AI investments and partnerships.